Navigation Links
Synosia Therapeutics Announces Appointment of Chief Business Officer
Date:12/13/2007

SAN FRANCISCO, December 13 /PRNewswire/ -- Synosia Therapeutics today announced the appointment of Antony Blanc, Ph.D., as the company's new chief business officer, effective immediately.

Dr Blanc, who will serve as head of Synosia's office in Basel, Switzerland, joins from Syngenta, where he created and led the biopharmaceuticals business unit. A molecular biologist by training and an experienced biotech entrepreneur, Dr. Blanc helped biotech and pharma clients with R&D, commercial and strategy issues as associate partner with the business consultants McKinsey & Company.

"With a strong entrepreneurial flair in biotech and expertise in both science and business, Antony Blanc brings together the skills we need to lead our increasingly important presence in Switzerland," said Synosia Chief Executive Officer and President Dr. Ian Massey. "Our three pharmaceutical partners are based in Basel and this appointment will give us the leadership we need in Europe to meet our ambitious goals for 2008, including the start of four phase II trials."

"Synosia has a broad clinical-stage portfolio with several advanced molecules, highly experienced leaders, a well-aligned and strong investor base and a grounding in both the US and in Switzerland. I look forward to building on this promising combination to create a leading CNS-focused specialty pharma company" said Blanc.

Antony Blanc replaces Herve Girsault M.B.A., who will remain on Synosia's board of directors and continue to act as a key business advisor to the company.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta, including two marketed drugs that will be tested in new indications, extending their reach
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Shimadzu Scientific Instruments introduces its ... for the pain management and clinical markets. The software ... review by allowing users to highlight and review results ... QuantAnalytics allows analysts to filter results by group or ... by eliminating the need to sift through analytes of ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark ... of treating lung, brain, pancreatic, breast and colon cancers ... overexpression (also called EGFR or c-ErbB-1). The patent ... / S-Phase cytotoxic protocols achieve only a fraction of ...
... HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, March ... diagnostics,today announced that the Company is scheduled to ... Biotech Industry" Conference on Thursday,April 2, 2009. Presented ... has built a reputation as a major biotech ...
... SUNNYVALE, Calif. March 24 Cepheid (Nasdaq: ... revolutionize the speed of diagnosis of Mycobacterium tuberculosis ... for the disease.The new test technology, developed in partnership ... University of Medicine and Dentistry of New Jersey ...
Cached Biology Technology:Patent for Making Combination Chemotherapy Work Better 2Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 2Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 3Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 4Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 5Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 6
(Date:10/22/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... for its third quarter ended September 30, 2014. ... an increase of 40% compared to $4.3 million in the ... of 2014 was $4.1 million compared to $1.0 million in ... current three month period was primarily due to: i) a ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
... recently discovered compound from the aminopyridine class not only has ... all strains of malaria, but might also be able to ... to a research collaboration involving the Medicines for Malaria Venture ... Centre (H3-D) at the University of Cape Town, South Africa. ...
... cells perform an array of essential functions, including cell ... and out of cells. They are critical targets for ... as disease biomarkers early warning beacons announcing the ... study of the binding properties of membrane proteins is ...
... Disruptions to the circadian rhythm can affect the growth of ... diabetes, obesity, and cancer, according to a new study from ... is regulated by a "clock" that reacts to both incoming ... in the scientific journal Cell Reports , it is ...
Cached Biology News:African research identifies strong candidate for possible single-dose malaria cure 2African research identifies strong candidate for possible single-dose malaria cure 3A new look at proteins in living cells 2A new look at proteins in living cells 3A new look at proteins in living cells 4
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... 2D is an automated, two-dimensional fractionation system ... Part of Beckman Coulters ProteomeLab family ... in just hours. The system effectively ... cell lysates, addressing a key challenge in ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... HORIBA Jobin Yvons Protein 295 ex ... a protein sample in only a few ... the amino acids tyrosine and tryptophan, the ... powerful NanoLED-17, a pulsed diode emitting 295 ...
Biology Products: